I went ahead and asked ai why Doc J might decide to wait. I framed as "rollover delayed 48 weeks and requiring patients to progress." Just pasting some of the reasons. Some or maybe most are/were obvious
Pre PS. AI thinks Natera has been collecting and analyzing data for us all along but that it was just announced. I'm not sure if cydy ever mentioned them before.
A little too long. Again some is obvious
"When Natera's Signatera assay picks up deep ctDNA clearance loops during this parent period, it mathematically isolates leronlimab as the exact driver of efficacy. It removes the "co-dependency" discount, proving the asset has standalone anti-tumor power before an ICI is even touched".
"The Business Advantage: The holy grail for a Big Pharma Chief Scientific Officer (CSO) is a paired tissue biopsy showing exactly how a microenvironment fortress was dismantled. [2]
* The Execution: When a patient eventually progresses on the parent study and enters the rollover protocol, CytoDyn obtains fresh tumor biopsies. By comparing this progression tissue directly with baseline samples, they can correlate real-time changes in the tumor microenvironment (such as the collapse of the pancreatic or colorectal desmoplastic stroma and the decline of LAG-3/TIM-3 exhaustion markers). This biopsy vault provides the definitive structural proof that the "Pre-ICI Trap" has been successfully set in a real human being
"4. Turning a "Failing" Patient Into a Multi-Billion Dollar Salvage Asset
* The Business Advantage: Standard immunotherapies have a 0% response rate in progressed, cold MSS colorectal cancer. If leronlimab can save these patients, it owns the most lucrative indication in oncology.
* The Execution: When a patient progresses at week 48, they are technically a clinical failure under standard of care. By introducing the Leronlimab + ICI combination only at this exact moment, Dr. Lalezari is setting up a high-stakes clinical demonstration. If the combination subsequently triggers a dramatic, vertical ctDNA rescue or a long-lasting remission—identical to the 5 out of 5 terminal mTNBC patients who achieved long-term survival at ESMO—CytoDyn proves it can salvage a multi-billion dollar market that Big Pharma had completely written off as dead.
..."By delaying the ICI, CytoDyn forces Big Pharma to view the data in two completely distinct, undeniable phases. They see that leronlimab works flawlessly on its own to flatten chemokine gradients, and they see that it functions as a necessary companion that saves their failing blockbusters when the tumor tries to escape. CytoDyn dictates the clinical narrative, controls the data, and retains absolute leverage over the timeline"...
I asked a 2nd question
Does Doc J make the decision knowing if they are meeting the treatment parameters necessary for mono approval.
A couple different snips:
..."plans are only modified mid-trial when the interim signal is so strong that sticking to the original protocol would actually dilute or confuse the data."...
..."Dr. Lalezari stated directly that introducing an ICI at that early stage would act as a confounding variable.
* The Logic: If he added the ICI immediately, critics and Big Pharma skeptics would claim the tumor shrinkage was just a late response to the chemo backbone or the ICI itself. By forcing patients to stay on leronlimab + chemotherapy up to the 48-week progression gate, he is letting the standalone asset prove its unassailable therapeutic value without statistical noise"...
..."Satisfying the FDA's "Individual Contribution" Rule
To gain approval for any combination drug, the FDA legally requires the sponsor to prove exactly what each individual drug contributes to the regimen. [2]
..." The Evidence: By holding back the ICI until after documented disease progression, CytoDyn satisfies this strict mandate"....
Pre PS. AI thinks Natera has been collecting and analyzing data for us all along but that it was just announced. I'm not sure if cydy ever mentioned them before.
A little too long. Again some is obvious
"When Natera's Signatera assay picks up deep ctDNA clearance loops during this parent period, it mathematically isolates leronlimab as the exact driver of efficacy. It removes the "co-dependency" discount, proving the asset has standalone anti-tumor power before an ICI is even touched".
"The Business Advantage: The holy grail for a Big Pharma Chief Scientific Officer (CSO) is a paired tissue biopsy showing exactly how a microenvironment fortress was dismantled. [2]
* The Execution: When a patient eventually progresses on the parent study and enters the rollover protocol, CytoDyn obtains fresh tumor biopsies. By comparing this progression tissue directly with baseline samples, they can correlate real-time changes in the tumor microenvironment (such as the collapse of the pancreatic or colorectal desmoplastic stroma and the decline of LAG-3/TIM-3 exhaustion markers). This biopsy vault provides the definitive structural proof that the "Pre-ICI Trap" has been successfully set in a real human being
"4. Turning a "Failing" Patient Into a Multi-Billion Dollar Salvage Asset
* The Business Advantage: Standard immunotherapies have a 0% response rate in progressed, cold MSS colorectal cancer. If leronlimab can save these patients, it owns the most lucrative indication in oncology.
* The Execution: When a patient progresses at week 48, they are technically a clinical failure under standard of care. By introducing the Leronlimab + ICI combination only at this exact moment, Dr. Lalezari is setting up a high-stakes clinical demonstration. If the combination subsequently triggers a dramatic, vertical ctDNA rescue or a long-lasting remission—identical to the 5 out of 5 terminal mTNBC patients who achieved long-term survival at ESMO—CytoDyn proves it can salvage a multi-billion dollar market that Big Pharma had completely written off as dead.
..."By delaying the ICI, CytoDyn forces Big Pharma to view the data in two completely distinct, undeniable phases. They see that leronlimab works flawlessly on its own to flatten chemokine gradients, and they see that it functions as a necessary companion that saves their failing blockbusters when the tumor tries to escape. CytoDyn dictates the clinical narrative, controls the data, and retains absolute leverage over the timeline"...
I asked a 2nd question
Does Doc J make the decision knowing if they are meeting the treatment parameters necessary for mono approval.
A couple different snips:
..."plans are only modified mid-trial when the interim signal is so strong that sticking to the original protocol would actually dilute or confuse the data."...
..."Dr. Lalezari stated directly that introducing an ICI at that early stage would act as a confounding variable.
* The Logic: If he added the ICI immediately, critics and Big Pharma skeptics would claim the tumor shrinkage was just a late response to the chemo backbone or the ICI itself. By forcing patients to stay on leronlimab + chemotherapy up to the 48-week progression gate, he is letting the standalone asset prove its unassailable therapeutic value without statistical noise"...
..."Satisfying the FDA's "Individual Contribution" Rule
To gain approval for any combination drug, the FDA legally requires the sponsor to prove exactly what each individual drug contributes to the regimen. [2]
..." The Evidence: By holding back the ICI until after documented disease progression, CytoDyn satisfies this strict mandate"....
7
